GESSEL advised on two public offerings of Bioceltix shares with a total value of over PLN 116 million

GESSEL provided comprehensive legal advice to Bioceltix S.A. (the “Company”), a Wrocław-based biotech company, in connection with a public offering of shares conducted through an accelerated book-building process (ABB) by the Company’s shareholders: Alternative Solution Alternatywna Spółka Inwestycyjna S.A. and Kvarko Group Alternatywna Spółka Inwestycyjna sp. z o.o. At the same time, with the firm’s support, the Company conducted two new share issues to be subscribed for by the shareholders using funds obtained from the ABB. The total value of the transaction amounts to PLN 116,194,590.00.

Given the strong investor demand exceeding the initial size of the shareholders’ offering, the additional allotment option for existing shares was exercised, and the size of the offering was duly increased. GESSEL was responsible for preparing the transaction documentation and for current legal support and advice to the Company and the investment firms mBank S.A. and Trigon Dom Maklerski S.A. at every stage of the transaction.

“I am very pleased that, thanks to my team’s experience, we could support Bioceltix, its shareholders, and the advisors with effective legal solutions that enabled the achievement of ambitious investment goals. We are grateful for the continued trust placed in us and wish Bioceltix success in implementing its strategy,” commented Krzysztof Marczuk, Partner at GESSEL.

The offering managers for the transaction were mBank S.A. and Trigon Dom Maklerski S.A., responsible for coordinating the ABB process and placing the shares among institutional investors. cc group sp. z o.o. acted as the Company’s investor relations advisor.